Skip Nav Destination
1-9 of 9
Keywords: Tyrosine kinase inhibitorsClose
Francesco Tarantini, Cosimo Cumbo, Elisa Parciante, Luisa Anelli, Antonella Zagaria, Nicoletta Coccaro, Crescenzio Francesco Minervini, Giuseppina Tota, Immacolata Redavid, Maria Rosa Conserva, Immacolata Attolico, Antonella Russo Rossi, Giorgina Specchia, Pellegrino Musto, Francesco Albano
Acta Haematol (2023) 146 (1): 39–45.
Published Online: 14 March 2023
... to treatment. Methods: We evaluated the IRF4 expression kinetics during tyrosine kinase inhibitor (TKI) treatment in a cohort of 116 chronic myeloid leukemia (CML) patients to elucidate its role in the disease course. Results: A relationship between the IRF4 expression and the disease burden was observed...
Abhishek Maiti, Miguel J. Franquiz, Farhad Ravandi, Jorge E. Cortes, Elias J. Jabbour, Koji Sasaki, Kayleigh Marx, Naval G. Daver, Tapan M. Kadia, Marina Y. Konopleva, Lucia Masarova, Gautam Borthakur, Courtney D. DiNardo, Kiran Naqvi, Sherry Pierce, Hagop M. Kantarjian, Nicholas J. Short
Acta Haematol (2020) 143 (6): 567–573.
Published Online: 09 February 2021
... Background: Philadelphia chromosome-positive (Ph+) advanced leukemias, including acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) in myeloid blast phase (MBP), have poor outcomes. Venetoclax has shown synergism with BCR-ABL1 tyrosine kinase inhibitors (TKI) in preclinical studies. However...
Bachar Samra, Hagop M. Kantarjian, Koji Sasaki, Ahmad S. Alotaibi, Marina Konopleva, Susan O’Brien, Alessandra Ferrajoli, Rebecca Garris, Cesar A. Nunez, Tapan M. Kadia, Nicholas J. Short, Elias Jabbour
Acta Haematol (2021) 144 (3): 285–292.
Published Online: 25 November 2020
...Bachar Samra; Hagop M. Kantarjian; Koji Sasaki; Ahmad S. Alotaibi; Marina Konopleva; Susan O’Brien; Alessandra Ferrajoli; Rebecca Garris; Cesar A. Nunez; Tapan M. Kadia; Nicholas J. Short; Elias Jabbour Background: The addition of tyrosine kinase inhibitors (TKIs) to chemotherapy has dramatically...
Acta Haematol (2020) 143 (3): 191–193.
Published Online: 12 September 2019
... or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Tyrosine kinase inhibitors Age Comorbidities Feasibility of discontinuation Quality...
Acta Haematol (2015) 134 (3): 161–167.
Published Online: 09 May 2015
... conditions associated with CML at different times during the course of the disease. All 8 patients were treated with tyrosine kinase inhibitors at some point during the course of their illness. The literature regarding the uncommon association of these apparently unrelated disorders is reviewed as well...
Agueda Molinos-Quintana, Virginia Aquino, Isabel Montero, Concepción Pérez-de Soto, Raúl García-Lozano, José Antonio Pérez-Simón, José María Pérez-Hurtado
Acta Haematol (2015) 134 (2): 71–75.
Published Online: 18 April 2015
...-ABL Philadelphia chromosome-positive acute lymphoblastic leukaemia. We detected three BCR-ABL1 clones determined by the presence of the E255V, D276G and F317L mutations. We point out the usefulness of searching for mutated populations that survive tyrosine-kinase inhibitor therapy and the role...
Aline Fernanda Ferreira, Gislane L.V. de Oliveira, Raquel Tognon, Maria Dulce S. Collassanti, Maria Aparecida Zanichelli, Nelson Hamerschlak, Ana Maria de Souza, Dimas Tadeu Covas, Simone Kashima, Fabiola Attie de Castro
Acta Haematol (2015) 133 (4): 354–364.
Published Online: 17 February 2015
...Aline Fernanda Ferreira; Gislane L.V. de Oliveira; Raquel Tognon; Maria Dulce S. Collassanti; Maria Aparecida Zanichelli; Nelson Hamerschlak; Ana Maria de Souza; Dimas Tadeu Covas; Simone Kashima; Fabiola Attie de Castro Background/Aims: We investigated the effects of tyrosine kinase inhibitors...
Frauke Ringel, Jaspal Kaeda, Michaela Schwarz, Christian Oberender, Peggy Grille, Bernd Dörken, Fanny Marque, Paul W. Manley, Thomas Radimerski, Philipp le Coutre
Acta Haematol (2014) 132 (1): 75–86.
Published Online: 31 January 2014
... JAK2 mutation Tyrosine kinase inhibitors Chronic myeloproliferative neoplasms (CMPNs) are rare diseases of hematopoietic stem cells that are characterized by clonal expansion of one or more myeloid precursor cells. The four most frequent diseases of this group are chronic myelogenous leukemia...
Anthony Oyekunle, Evgeny Klyuchnikov, Sunday Ocheni, Nicolaus Kröger, Axel R. Zander, Michele Baccarani, Ulrike Bacher
Acta Haematol (2011) 126 (1): 30–39.
Published Online: 30 June 2011
...Anthony Oyekunle; Evgeny Klyuchnikov; Sunday Ocheni; Nicolaus Kröger; Axel R. Zander; Michele Baccarani; Ulrike Bacher Following the introduction of the tyrosine kinase inhibitor (TKI) imatinib in the treatment of chronic myeloid leukemia (CML) patients, the allogeneic hematopoietic stem cell...